DNTH · Dianthus Therapeutics Inc
United States · RS rating 32 · As of 2026-10-14
| Price | 74.76 USD |
|---|---|
| 1-day change | -3.6% |
| RS rating (overall / 1M / 3M / 12M) | 32 / 7 / 18 / 96 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 35 / 20 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -47.4% |
| Sales growth Q/Q | -28.3% |
| Distance from 52-week high | +35.5% |
| Market cap (USD) | $4.9B |